Biocard   Report issue

For profit Phase 1
Founded: Moscow Russian Federation (1989)

Organization Overview

First Clinical Trial
2016
NCT02722239
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (3)

dapagliflozin (farxiga) (1 trial)

sitagliptin (januvia) (1 trial)

xigduo (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 2 (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 3